No Data
Verona Pharma Is Maintained at Buy by Canaccord Genuity
Express News | Verona Pharma PLC : Canaccord Genuity Raises Target Price to $37 From $35
Analysts Have Conflicting Sentiments on These Healthcare Companies: Astellas Pharma (OtherALPMF) and Verona Pharma (VRNA)
CCORF Maintains Verona Pharma(VRNA.US) With Buy Rating, Raises Target Price to $37
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday; Set to End Week Down 4%
European Equities Traded in the US as American Depositary Receipts Trend Lower Thursday